Fast Market Research

Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H1 2016 - New Market Study Published

Fast Market Research announces the availability of the new Global Markets Direct report, "Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H1 2016", on their comprehensive research portal


Boston, MA -- (SBWIRE) -- 07/28/2016 -- Global Markets Direct's, 'Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H1 2016', provides an overview of the Kidney Cancer (Renal Cell Cancer) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Kidney Cancer (Renal Cell Cancer), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Kidney Cancer (Renal Cell Cancer) and features dormant and discontinued projects.

Get More Details on this Report and a Full Table of Contents at Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H1 2016

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Report Scope

-The report provides a snapshot of the global therapeutic landscape of Kidney Cancer (Renal Cell Cancer)

-The report reviews pipeline therapeutics for Kidney Cancer (Renal Cell Cancer) by companies and universities/research institutes based on information derived from company and industry-specific sources

-The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

-The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

-The report reviews key players involved Kidney Cancer (Renal Cell Cancer) therapeutics and enlists all their major and minor projects

-The report assesses Kidney Cancer (Renal Cell Cancer) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

-The report summarizes all the dormant and discontinued pipeline projects

-The report reviews latest news related to pipeline therapeutics for Kidney Cancer (Renal Cell Cancer)

Reasons to Get this Report

-Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

-Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

-Identify and understand important and diverse types of therapeutics under development for Kidney Cancer (Renal Cell Cancer)

-Identify potential new clients or partners in the target demographic

-Develop strategic initiatives by understanding the focus areas of leading companies

-Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

-Devise corrective measures for pipeline projects by understanding Kidney Cancer (Renal Cell Cancer) pipeline depth and focus of Indication therapeutics

-Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

-Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies Mentioned in this Report: 4SC AG, AbbVie Inc., Acceleron Pharma, Inc., Advanced Cancer Therapeutics, Advaxis, Inc., Advenchen Laboratories, LLC, Alethia Biotherapeutics Inc., Altor BioScience Corporation, Ambrx, Inc., Amgen Inc., Ampio Pharmaceuticals, Inc., Apcure SAS, APEIRON Biologics AG, arGEN-X BV, Argos Therapeutics, Inc., ArQule, Inc., Arrowhead Pharmaceuticals, Inc., Astellas Pharma Inc., AstraZeneca Plc, ATLAB Pharma SAS, Aurigene Discovery Technologies Limited, Bayer AG, Berg LLC, BIND Therapeutics, Inc., Bio-Cancer Treatment International Limited, BIOCAD, Bionomics Limited, Bionovis SA, Boehringer Ingelheim GmbH, Boston Biomedical, Inc., Bristol-Myers Squibb Company, Caladrius Biosciences, Inc., Calithera Biosciences, Inc., CASI Pharmaceuticals Inc., Celgene Corporation, Cellceutix Corporation, Celldex Therapeutics, Inc., Celltrion, Inc., Cellular Biomedicine Group, Inc., Cerulean Pharma, Inc., Chipscreen Biosciences Ltd, Clonz Biotech Private Limited, Coare Biotechnology, Inc., Coherus BioSciences, Inc., Corcept Therapeutics Incorporated, Corvus Pharmaceuticals, Inc., Cytune Pharma SAS, Dr. Reddy's Laboratories Limited, Ecrins Therapeutics SAS, EirGenix Inc., Eisai Co., Ltd., Eli Lilly and Company, Esperance Pharmaceuticals, Inc., Exelixis, Inc., F. Hoffmann-La Roche Ltd., Gene Techno Science Co., Ltd., Genor BioPharma Co., Ltd., GenSpera, Inc., GlaxoSmithKline Plc, Glycotope GmbH, HEC Pharm Co., Ltd., Horizon Pharma Plc, Hutchison MediPharma Limited, Immatics Biotechnologies GmbH, Immune Design Corp., Immunicum AB, ImmunoFrontier, Inc., ImmunoGen, Inc., Immunomedics, Inc., Incuron, LLC, Incyte Corporation, Innate Immunotherapeutics Ltd, Johnson & Johnson, KAHR medical Ltd., Karyopharm Therapeutics, Inc., KineMed, Inc., Komipharm International Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Lead Discovery Center GmbH, Mabion SA, MacroGenics, Inc., MaxiVAX SA, MediaPharma s.r.l., MedImmune, LLC, Medivation, Inc., Merck & Co., Inc., Merck KGaA, Millennium Pharmaceuticals, Inc., Mirati Therapeutics Inc., Mirna Therapeutics, Inc., Molecular Partners AG, Mologen AG, Monopar Therapeutics LLC, Mycenax Biotech Inc., NanoSmart Pharmaceuticals, Inc., Nektar Therapeutics, NewLink Genetics Corporation, Novartis AG, NovaTarg Therapeutics, Inc, Omeros Corporation, OncBioMune Pharmaceuticals Inc., Oncobiologics, Inc., Oncolys BioPharma Inc., OncoMax, Ono Pharmaceutical Co., Ltd., Panacea Biotec Limited, Peloton Therapeutics, Inc., Pfizer Inc., Pharmicell Co., Ltd., Pivotal BioSciences, Inc., Plexxikon Inc., Prima BioMed Ltd., PsiOxus Therapeutics Limited, Qu Biologics Inc., Recombio S.L, Rexahn Pharmaceuticals, Inc., Sanofi, Seattle Genetics, Inc., Selvita S.A., Sevion Therapeutics, Inc., Shanghai Henlius Biotech Co., Ltd., Sillajen Biotherapeutics, Sorrento Therapeutics, Inc., Sumitomo Dainippon Pharma Co., Ltd., Syndax Pharmaceuticals, Inc., Synthon Holdings BV, Taiwan Liposome Company, Ltd., Takeda Pharmaceutical Company Limited, Tara Immuno-Oncology Therapeutics LLC, Taris Biomedical LLC, TC BioPharm Limited, Teva Pharmaceutical Industries Ltd., Theravectys SA, Threshold Pharmaceuticals, Inc., Tocagen Inc., TRACON Pharmaceuticals, Inc., TVAX Biomedical, Inc., Tyrogenex, Inc., United BioPharma, Inc., UroGen Pharmaceuticals, Ltd., Vascular Biogenics Ltd., Vault Pharma Inc., Vaxeal Holding SA, ViiV Healthcare Limited, Vyriad, X4 Pharmaceuticals, Inc.

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156.

Browse all Drug Pipeline research reports at Fast Market Research